"Genentech provides scientists with the unique opportunity to do ground-breaking science with the goal of developing innovative therapies for patients."
I joined Genentech in 2007 after my postdoctoral training at Yale University where I studied the cellular mechanisms underlying the unique capacity of dendritic cells to capture and present antigens for T cell priming. At Genentech in the Cancer Immunology Department, I have been pursuing my research interests with the goal of developing novel approaches to expand effective T cell responses to cancer through priming. I feel extremely fortunate to be surrounded by colleagues with various scientific background who are highly enthusiastic, engaged, and eager to collaborate. They inspire me to give my best.
Nature. 2014 Nov 27;515(7528):572-6.
The research projects in my lab have been focused on exploring novel approaches to expand anti-tumor T cell responses through priming. Recently we focused on the identification of the tumor antigens that shape immune responses to cancer. We and others have shown that mutations, also called neo-antigens, that accumulate in cancer are highly immunogenic and can drive protective T cell responses against cancer.
The recent advent of next generation sequencing technologies has enabled rapid and comprehensive discovery of cancer-specific mutations in individual patients and provides the opportunity to develop novel approaches to selectively target neoantigens.